# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 41-50 of 566 results.
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Jun 28, 2019
First Received: Jun 28, 2019
Disease(s): Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Intervention(s): TQB2450
Locations: Peking University First Hospital, Beijing, Beijing, China
Fifth Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijin, Beijing, China
Peking Hospital, Beijin, Beijing, China
... and 14 other locations.
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Oct 14, 2019
First Received: Sep 07, 2017
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Vincristine Placebo, Prednisone, Polatuzumab vedotin Placebo
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Southern Cancer Center, Daphne, Alabama, United States
City of Hope, Duarte, California, United States
Ronald Reagan UCLA Medical Center; Drug Information Center, Los Angeles, California, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
... and 253 other locations.
Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 14, 2015
First Received: May 20, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Locations: DiDeng, Wuhan, Hubei, China
The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Dec 14, 2015
First Received: May 20, 2015
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Consolidation involved-site radiotherapy (ISRT), Consolidation involved-field radiotherapy (IFRT), cyclophosphamide, doxorubicin, vincristine, prednisone
Locations: DiDeng, Wuhan, Hubei, China
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation
Status: Recruiting
Last Changed: Apr 24, 2019
First Received: Feb 26, 2016
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): Ibrutinib, Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone
Locations: Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
Hospital Especialidades, Jerez de la Frontera, Cádiz, Spain
Hospital Universitario Donostia, Donostia San Sebastian, Guipúzcoa, Spain
Hospital Universitario Son Espases, Palma, Islas Baleares, Spain
Hospital de Navarra, Pamplona, Navarra, Spain
... and 13 other locations.
A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting
Last Changed: Sep 14, 2018
First Received: Jul 06, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Decitabine
Locations: Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 19, 2019
First Received: Jul 18, 2018
Disease(s): Diffuse Large B-Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
Intervention(s): Loncastuximab tesirine
Locations: City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
Compassionate Care Research Group, Inc., at Compassionate Care Medical Group, Inc., Fountain Valley, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California, San Francisco Medical Center, San Francisco, California, United States
The Oncology Institute of Hope and Innovation, Whittier, California, United States
... and 33 other locations.
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Not yet recruiting
Last Changed: May 03, 2019
First Received: May 03, 2019
Disease(s): Diffuse Large B-cell Lymphoma (DLBCL)
Intervention(s): abexinostat
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
Status: Recruiting
Last Changed: May 06, 2019
First Received: May 16, 2012
Disease(s): Primary Mediastinal B-cell Lymphoma
Intervention(s): observation, 3D-Conformal Radiotherapy (3D-CRT)
Locations: Norton Cancer Institute, Louisville, Kentucky, United States
Mayo Clinil Rocheser, Rochester, Minnesota, United States
MD Anderson Cancer Center, Houston, Texas, United States
Centro de Hematologia y Oncologia Pavlovsky, Buenos Aires, Argentina
Princess Margaret Hospital, Toronto, Canada
... and 87 other locations.
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Status: Recruiting
Last Changed: Jan 04, 2019
First Received: Jun 15, 2015
Disease(s): Diffuse Large B-Cell Lymphoma
Intervention(s): KPT-330, Rituximab, Etoposide, Carboplatin, Ifosfamide, Dexamethasone
Locations: Weill Cornell Medical College, New York, New York, United States